Aclarion (ACON) Competitors

Biorestorative Therapies (NASDAQ:BRTX) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Does the media prefer BRTX or ACON?

In the previous week, Biorestorative Therapies and Biorestorative Therapies both had 1 articles in the media. Aclarion's average media sentiment score of 0.50 beat Biorestorative Therapies' score of 0.00 indicating that Aclarion is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biorestorative Therapies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, BRTX or ACON?

Aclarion has lower revenue, but higher earnings than Biorestorative Therapies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$400K	26.34	-$8.98M	-$1.47	-0.96
Aclarion	$54.60K	78.61	-$6.99M	N/A	N/A

Which has more risk and volatility, BRTX or ACON?

Biorestorative Therapies has a beta of 76.7, suggesting that its stock price is 7,570% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Do analysts recommend BRTX or ACON?

Biorestorative Therapies currently has a consensus target price of $18.00, suggesting a potential upside of 1,181.14%. Aclarion has a consensus target price of $11,758.50, suggesting a potential upside of 159,337.29%. Given Aclarion's higher probable upside, analysts clearly believe Aclarion is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aclarion	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is BRTX or ACON more profitable?

Biorestorative Therapies has a net margin of -3,093.61% compared to Aclarion's net margin of -12,227.10%. Aclarion's return on equity of -126.89% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,093.61%	-129.47%	-86.02%
Aclarion	-12,227.10%	-126.89%	-106.61%

Do institutionals and insiders have more ownership in BRTX or ACON?

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 25.5% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 0.8% of Aclarion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Biorestorative Therapies beats Aclarion on 8 of the 13 factors compared between the two stocks.